Journal
TRANSFUSION AND APHERESIS SCIENCE
Volume 37, Issue 2, Pages 191-200Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.transci.2007.08.003
Keywords
inflammatory bowel disease; granulocytes; proinfammatory CD14(+)CD16(+) monocytes; selective leukocytapheresis; regulatory CD4(+)CD25(+)Foxp3 T cells; Adacolumn
Categories
Ask authors/readers for more resources
The inference that granulocytes and monocytes/macrophages (GM) are part of the immunopathogenesis of inflammatory bowel disease (IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The Adacolumn can selectively deplete GM by adsorption (GMA) and in patients with IBD, GMA has been associated with significant clinical efficacy together with sustained suppression of inflammatory cytokine profiles. Additionally, GMA depleted proinflammatory CD 14(+)CD 16(+) monocytes and was followed by an increase in CD4(+) T lymphocytes including the regulatory CD4(+)CD25(high+)Foxp3 phenotype. Hence, GMA could be a non-pharmacologic therapy for IBD with potential to spare steroids and other unsafe pharmacologic preparations. (C) 2007 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available